摘要
目的 :观察卡维地洛治疗轻中度原发性高血压的疗效和安全性。方法 :随机单盲平行对照试验 ,符合条件的 5 4例轻中度原发性高血压患者随机分为 2组 :卡维地洛组 2 9例 ,柳胺苄心定组 2 5例。每日分别口服卡维地洛 2 0mg和柳胺苄心定 10 0mg ,分二次给药。每周随访 1次。 2周后 ,如患者舒张压 >90mmHg ,则剂量加倍 ,即卡维地洛 4 0mg、柳胺苄心定 2 0 0mg。疗程 4周。 结果 :(1)治疗 4周末 ,卡维地洛组降压总有效率79.3% ,柳胺苄心定组降压总有效率 84 .0 % ,两组比较无统计学差异。 (2 )卡维地洛组治疗前后收缩压下降幅度为 12 .4 % ,舒张压下降幅度 12 .9%。柳胺苄心定组治疗前后收缩压下降幅度为 11.8% ,舒张压下降幅度11.0 %。两组比较无统计学差异 (P >0 .0 5 )。 (3)不良反应的发生率相似 ,卡维地洛组为 10 .1% ,柳胺苄心定组为 19.2 % ,常见的不良反应为头晕、皮疹、丙氨酸转氨酶轻度升高 ,均较轻。结论 :卡维地洛 2 0mg/d～ 4 0mg/d ,治疗轻中度原发性高血压安全有效。
Objective: To observe the efficacy and safety of carvedilol in treating essential hypertension. Methods: Eligible mild and moderate essential hypertension patients were divided randomly into 2 groups: of which 29 received carvedilol (10 mg bid) and 25 received labetalol (50 mg bid) for 2 weeks. The doses of carvedilol and labetalol were double, if DBP still >90 mmHg remained after 2 weeks treatment. This trial continued for 4 weeks. Results: (1) After 4 weeks,the rate of effectiveness of carvedilol and labetalol were 79.3% and 84.0% respectively, there were no significant difference between the 2 groups. (2) After 4 weeks,the SBP and DBP of carvedilol group decreased 12.4% and 12.9% respectively, labetalol group decreased 11.8% and 11.0% respectively , no significant difference was observed . (3) A lower incidence of adverse effects was observed, such as mild dizziness?rash et al. Conclusion: Carvedilol (20 mg～40 mg/d) is effective and safe in treating mild to moderate essential hypertension.
出处
《中日友好医院学报》
2004年第2期77-80,共4页
Journal of China-Japan Friendship Hospital
